, under the accelerated approval program for treating patients with locally advanced or metastatic cholangiocarcinoma harboring anfusion or rearrangement. The same is for another recently approved FDA drug Incyte’s Pemazyre which will be Truseltiq’s main competitor for treating CCA harboringfusions could be helpful in helping clinicians make decisions regarding prescribing these drugs. Interestingly, this study also noted cholangiocarcinoma FFPE clinical specimens withmutations.
Aside from detecting RNA fusions, MSI analysis and TMB estimation that could help identify druggable mutations for targeted therapy selection, many actionable SNV/Indel can also be seen with a high sensitivity at a claimed limit detection of 5% VAF using this assay. An example is that of Exon 19 deletion in lung cancer that could inform the use of Tarceva , a tyrosine kinase inhibitor approved by the U.S.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: LeedsNews - 🏆 48. / 63 Read more »